News

August 7, 2019

Cure SMA Releases Status Update on Data Accuracy Issues with Zolgensma

Yesterday, the FDA issued a statement identifying data accuracy issues with Avexis’ SMA therapy, Zolgensma. Cure SMA is in communication with the FDA and is committed to representing the SMA patient voice and...

READ MORE   |  

Topics: Front Page News

August 6, 2019

FDA Issues Statement on Data Accuracy Issues with Recently Approved Gene Therapy

Today, the FDA issued the below statement identifying data accuracy issues with AveXis’ SMA therapy, Zolgensma. Cure SMA is investigating this issue and will report when we have further details. We will be...

READ MORE   |  

Topics: Front Page News

August 5, 2019

Biogen Issues Community Statement on Spinraza

Biogen Issues Community Statement on Spinraza

Biogen has provided the following community statement on Spinraza. 

Dear members of the SMA community,

Following a busy spring of data presentations at medical congresses and the annual Cure SMA Conference, we are pleased to provide updates on research highlighting...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

July 31, 2019

SMA Awareness Month 2019 Has Begun!

SMA Awareness Month 2019 Has Begun!

The SMA community officially recognizes August as Spinal Muscular Atrophy Awareness Month and Cure SMA has been coordinating activities since 1996. August is a great time to spotlight the work our community does year-round to raise awareness of and funds for SMA.

In addition to our...

READ MORE   |  

Topics: Community & Awareness, Front Page News

July 24, 2019

Cure SMA Welcomes the New North Florida and Oklahoma Chapters

Cure SMA Welcomes the New North Florida and Oklahoma Chapters

Cure SMA is pleased to announce the creation of two new chapters: North Florida and Oklahoma. The chapters are eager to begin helping families throughout these areas and fundraising to support research to find a cure for SMA.

The Oklahoma Chapter will be led by chairpersons Amanda...

READ MORE   |  

Topics: Community & Awareness, Events & Fundraising, Front Page News

July 1, 2019

Biogen Announces New NURTURE Data at the 2019 Annual SMA Conference

Biogen Announces New NURTURE Data at the 2019 Annual SMA Conference

Biogen today announced new results from the NURTURE study, adding data to the longest study of spinal muscular atrophy (SMA) in pre-symptomatic...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

June 28, 2019

Updated SMA Drug Pipeline Now Available

Updated SMA Drug Pipeline Now Available

We’ve recently released an update to the SMA drug pipeline. This latest version includes:

  • 23 active programs, including two approved therapies.
  • 15 pharmaceutical partners.
  • 6 programs in clinical trials.
  • An ever-increasing breadth of potential...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

June 28, 2019

Cytokinetics Releases New Data from Reldesemtiv Clinical Study at the 2019 Annual SMA Conference

Cytokinetics Releases New Data from Reldesemtiv Clinical Study at the 2019 Annual SMA Conference

Cytokinetics, Incorporated, today announced that data from two preclinical studies of reldesemtiv were presented at the 2019 Annual Cure SMA...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

June 26, 2019

What People Are Saying: 2019 North Jersey Walk-n-Roll

What People Are Saying: 2019 North Jersey Walk-n-Roll

The North Jersey Cure SMA Chapter held their 4th annual North Jersey Walk-n-Roll on June 22, 2019 at the Roosevelt Park. Walk-n-Roll is a...

READ MORE   |  

Topics: Community & Awareness, Events & Fundraising, Front Page News

June 26, 2019

The 2019 Annual SMA Conference is Here!

The 2019 Annual SMA Conference is Here!

The 2019 Annual SMA Conference, now in its 31st year, is set to kick off on June 28 and continue into a weekend full of programs and events that bring families, researchers and healthcare professionals...

READ MORE   |  

Topics: Conference, Front Page News

Items 1 - 10 of 657  12345678910Next

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software